Palisade Bio Advances PALI-2108 into Phase 2 Trials, Extending Timeline to 2027 Readout

What happened

Palisade Bio has transitioned PALI-2108 from Phase 1b to Phase 2 development, with the first patient dosed in the global Phase 2b ASCENTRA-UC trial for ulcerative colitis and FDA clearance received for the Phase 2a ASCENTRA-CD trial in Crohn’s disease, targeting enrollment in Q1 2027. Topline UC results are now expected in Q4 2027, pushing the key value inflection point further out while providing a concrete timeline. The company ended Q3 2026 with $113.6 million in cash, sufficient to fund operations through those readouts per management. New clinical and translational data presented at ACG and UEG Week 2026 continue to support PALI-2108’s targeted profile, though they remain early and non-pivotal. This progress reduces regulatory and operational uncertainty but leaves the single-asset, binary risk profile largely unchanged.

Implication

Investors should view the start of Phase 2b UC and FDA clearance for Phase 2a CD as meaningful milestones that lower the probability of near-term regulatory failure, yet no efficacy data from these trials will be available until late 2027 at the earliest. The $113.6 million cash balance likely funds the company through those readouts, but additional capital will be required for further development, creating ongoing dilution risk. The investment remains a binary bet on PALI-2108’s success in ulcerative colitis and fibrostenotic Crohn’s disease, with no other pipeline assets providing downside support. Given the extended timeline and single-asset concentration, the current valuation probably embeds a moderate probability of success, and we see a more favorable risk-reward on pullbacks or after clearer clinical signals. Until then, investors should size positions conservatively and monitor enrollment progress, FDA interactions, and any signs of partnership interest.

Thesis delta

The investment thesis is unchanged in direction but modestly strengthened: Palisade has now initiated Phase 2b UC and received FDA clearance for Phase 2a CD, reducing execution risk relative to our prior expectations. However, value-driving efficacy data remain over a year away, and the stock still carries substantial binary, single-asset risk. We maintain our WAIT rating and would consider a more constructive stance only on successful Phase 2 interim signals or a significant pullback below $1.30.